{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"MTAPESTRY 103","nct_id":"NCT06360354","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mtapestry-103-nct06360354. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MTAPESTRY 103","arms":[{"description":"Part 1: Participants with MTAP-deleted PDAC will receive doses of Anvumetostat orally in combination with gemcitabine and nab-paclitaxel IV.\n\nPart 2: Participants with MTAP-deleted PDAC will receive the recommended dose of Anvumetostat in combination with gemcitabine and nab-paclitaxel.","label":"Subprotocol B: Pancreatic Ductal Adenocarcinoma (PDAC) Arm A","type":"EXPERIMENTAL"},{"description":"Part 1: Participants with MTAP-deleted PDAC will receive doses of Anvumetostat orally in combination with mFOLFIRINOX (irinotecan, fluorouracil, leucovorin calcium, oxaliplatin) IV.\n\nPart 2: Participants with MTAP-deleted PDAC will receive the recommended dose of Anvumetostat in combination with mFOLFIRINOX.","label":"Subprotocol B: PDAC Arm B","type":"EXPERIMENTAL"},{"description":"Part 1: Participants with MTAP-deleted PDAC will receive oral doses of Anvumetostat and RMC-6236.","label":"Subprotocol C: Dose Exploration","type":"EXPERIMENTAL"},{"description":"Part 2: Participants with MTAP-deleted PDAC will receive oral doses of Anvumetostat andRMC-6236.","label":"Subprotocol C: Dose Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-11-30","type":"ESTIMATED"},"conditions":["Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers"],"enrollment":{"count":120,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Anvumetostat","otherNames":["AMG 193"],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Modified FOLFIRINOX","otherNames":[],"type":"DRUG"},{"name":"RMC-6236","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-01","lead_sponsor":"Amgen","official_title":"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Anvumetostat in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-10-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Participants Experiencing Dose Limiting Toxicities (DLT)","timeFrame":"Up to 28 days"},{"measure":"Number of Participants Experiencing Treatment Emergent Adverse Events (TEAE)","timeFrame":"Up to approximately 2 years"},{"measure":"Number of Participants Experiencing Serious Adverse Events (SAE)","timeFrame":"Up to approximately 2 years"}],"references":[],"start_date":{"date":"2024-05-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","url":"https://clinicaltrials.gov/study/NCT06360354"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mtapestry-103-nct06360354"}